References
Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res. Oct 1 2019;25(19):5843–5851.
Kobayashi S, Takahashi S, Takahashi N, et al. Survival outcomes of resected BRAF V600E mutant colorectal liver metastases: a multicenter retrospective cohort study in Japan. Ann Surg Oncol. Jul 13 2020.
Nakamura Y, Taniguchi H, Ikeda M, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. Oct 5 2020.
Kobayashi S, Nakamura Y, Taniguchi H, et al. Impact of preoperative circulating tumor DNA status on survival outcomes after hepatectomy for resectable colorectal liver metastases. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-020-09449-8.
Kobayashi S. Multi-center clinical trial for personalized perioperative chemotherapy based on genetic alteration status for resectable oligometastases from colorectal cancer. 2020; https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000048502. Accessed 19th November, 2020.
Acknowledgements
This study received financial support from the National Cancer Center Research Development Fund (Research Number: 30-A-8, Principal investigator: Shinichiro Takahashi).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors disclose potential conflicts of interest as follows: Yoshiaki Nakamura, research funding from Taiho pharmaceutical company and Genomedia Inc.; Hiroya Taniguchi, honoraria from Takeda, Chugai, and Taiho pharmaceutical companies. Research funding from Takeda, Daiichi-Sankyo, Taiho, Ono Pharmaceutical companies; Takayuki Yoshino, research funding from Novartis Pharma, MSD, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Sanofi, Daiichi Sankyo, Parexel International, Ono Pharmaceutical, and GlaxoSmithKline companies.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kobayashi, S., Nakamura, Y., Takahashi, S. et al. ASO Author Reflections: Circulating Tumor DNA (ctDNA) as a Potentially Practice-Changing Innovation to Evolve “Precision Onco-Surgery” in Resectable Colorectal Liver Metastases. Ann Surg Oncol 28, 4756–4757 (2021). https://doi.org/10.1245/s10434-020-09456-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09456-9